Plain-English translation of NCT07185932 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing rifaximin, an antibiotic medication taken by mouth, to see if it can help treat metabolic-associated fatty liver disease — a condition where fat accumulates in the liver due to obesity, diabetes, or other metabolic problems. Researchers want to learn whether this medication can reduce the amount of fat in your liver and understand how it works. You'll take the medication for up to 24 weeks, and the researchers will monitor your liver health with special imaging scans.
Many people develop fatty liver disease linked to metabolic disorders like obesity and diabetes, and there are limited treatment options available right now. This trial is exploring whether this medication — which affects gut bacteria — might help reduce liver fat and improve liver health in patients with this condition.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth three times daily for 24 weeks while maintaining your usual diet and physical activity level. During this time, you'll have regular check-ups to monitor your liver health using blood tests and MRI scans. If your liver fat remains elevated after 24 weeks, you may continue treatment for up to 12 additional weeks. After you finish taking the medication, you'll return for follow-up visits over the next 24 weeks so researchers can track how your liver responds after treatment ends.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China